留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读

袁群生 李雪梅

袁群生, 李雪梅. 2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读[J]. 协和医学杂志, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
引用本文: 袁群生, 李雪梅. 2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读[J]. 协和医学杂志, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
Qun-sheng YUAN, Xue-mei LI. Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
Citation: Qun-sheng YUAN, Xue-mei LI. Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005

2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读

doi: 10.3969/j.issn.1674-9081.2018.03.005
详细信息
    通讯作者:

    李雪梅 电话:010-69154056, E-mail:lixmpumch@126.com

  • 中图分类号: R58

Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder

More Information
  • 摘要: 2009年改善全球肾脏病预后组织(kidney disease:improving global outcomes, KDIGO)发布了关于慢性肾脏病矿物质及骨异常(chronic kidney disease-mineral and bone disorder, CKD-MBD)的诊断、评估、预防和治疗的临床实践指南, 为广大临床工作者对CKD-MBD的认识及诊疗提供了详细的指导意见。但指南缺少针对临床终点事件的随机对照研究(randomized control trial, RCT)证据, 故其证据质量不高。随着此后多项RCT研究和前瞻性队列研究结果的公布, KDIGO工作组经过对相关新证据的评估和充分讨论, 于2017年6月对该指南进行了选择性更新, 主要涉及CKD-MBD中骨病的诊断及钙、磷和甲状旁腺素的管理等。本文就主要的更新内容进行解读, 揭示其临床意义。
  • [1] Kidney disease:improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2009, 76:S1-S130. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM19644521
    [2] Kidney disease:improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7:1-59. doi:  10.1016/j.kisu.2017.04.001
    [3] Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease[J]. Kidney Int, 2000, 58:396-399. doi:  10.1046/j.1523-1755.2000.00178.x
    [4] Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States[J]. J Am Soc Nephrol, 2006, 17:3223-3232. doi:  10.1681/ASN.2005111194
    [5] Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population[J]. Am J Kidney Dis, 2004, 44:672-679. doi:  10.1016/S0272-6386(04)00958-8
    [6] Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients[J]. Kidney Int, 2014, 85:166-173. doi:  10.1038/ki.2013.279
    [7] Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bonemineral density and biochemical markers of bone turnover inpredicting fracture in CKD stage 5D patients-a single-centercohort study[J]. Nephrol Dial Transplant, 2012, 27:345-351. doi:  10.1093/ndt/gfr317
    [8] West SL, Lok CE, Langsetmo L, et al. Bone mineral density predictsfractures in chronic kidney disease[J]. J Bone Miner Res, 2015, 30:913-919. doi:  10.1002/jbmr.2406
    [9] Haghverdi F, Mortaji S, Soltani P, et al. Effect of raloxifene onparathyroid hormone in osteopenic and osteoporoticpostmenopausal women with chronic kidney disease stage 5[J]. Iran J Kidney Dis, 2014, 8:461-466. http://europepmc.org/abstract/med/25362221
    [10] Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects ofdenosumab on fracture and bone mineral density by level of kidneyfunction[J]. J Bone Miner Res, 2011, 26:1829-1835. doi:  10.1002/jbmr.403
    [11] EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J]. N Engl J Med, 2012, 367:2482-2494. doi:  10.1056/NEJMoa1205624
    [12] Block GA, Kilpatrick RD, Lowe KA, et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization inpatients on hemodialysis[J]. Clin J Am Soc Nephrol, 2013, 8:2132-2140. doi:  10.2215/CJN.04260413
    [13] Chartsrisak K, Vipattawat K, Assanatham M, et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients[J]. BMC Nephrol, 2013, 14:14-20. doi:  10.1186/1471-2369-14-14
    [14] Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality inpatients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2010, 5:2251-2257. doi:  10.2215/CJN.00810110
    [15] Fouque D, Roth H, Pelletier S, et al. Control of mineral metabolism and bone disease in haemodialysis patients:which optimal targets?[J]. Nephrol Dial Transplant, 2013, 28:360-367. doi:  10.1093/ndt/gfs404
    [16] Gross P, Six I, Kamel S, et al. Vascular toxicity of phosphate in chronic kidney disease:beyond vascular calcification[J]. Circ J, 2014, 78:2339-2346. doi:  10.1253/circj.CJ-14-0735
    [17] Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease[J]. Kidney Int, 2013, 83:959-966. doi:  10.1038/ki.2012.403
    [18] Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD[J]. J Am Soc Nephrol, 2012, 23:1407-1415. doi:  10.1681/ASN.2012030223
    [19] Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders:a randomized study[J]. Clin J Am Soc Nephrol, 2012, 7:487-493. doi:  10.2215/CJN.03820411
    [20] Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients:results of an openlabel 24-month randomized clinical trial[J]. Am J Kidney Dis, 2013, 62:771-778. doi:  10.1053/j.ajkd.2013.03.023
    [21] Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality inpatients with chronic kidney disease:an updated systematic reviewand meta-analysis[J]. Lancet, 2013, 382:1268-1277. doi:  10.1016/S0140-6736(13)60897-1
    [22] Karavetian M, de Vries N, Elzein H, et al. Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients, Lebanon[J]. Patient Educ Couns, 2015, 98:1116-1122. doi:  10.1016/j.pec.2015.05.005
    [23] Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population[J]. Nephrol Dial Transplant, 2011, 26:1948-1955. doi:  10.1093/ndt/gfq219
    [24] Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets[J]. Kidney Int, 2012, 81:1116-1122. doi:  10.1038/ki.2011.490
    [25] St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006[J]. Clin J Am Soc Nephrol, 2009, 4:354-360. doi:  10.2215/CJN.05241008
    [26] Denburg MR, Tsampalieros AK, de Boer IH, et al. Mineral metabolism and cortical volumetric bone mineral density inchildhood chronic kidney disease[J]. J Clin Endocrinol Metab, 2013, 98:1930-1938. doi:  10.1210/jc.2012-4188
    [27] Ok E, Asci G, Bayraktaroglu S, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis[J]. J Am Soc Nephrol, 2016, 27:2475-2486. doi:  10.1681/ASN.2015030268
    [28] Spasovski G, Gelev S, Masin-Spasovska J, et al. Improve-ment of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium[J]. Bone, 2007, 41:698-703. doi:  10.1016/j.bone.2007.06.014
    [29] Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease:the PRIMO randomized controlled trial[J]. JAMA, 2012, 307:674-684. doi:  10.1001/jama.2012.120
    [30] Li XH, Feng L, Yang ZH, et al. The effect of active vitamin d on cardiovascular outcomes in predialysis chronic kidney diseases:a systematic review and meta-analysis[J]. Nephrology (Carlton), 2015, 20:706-714. doi:  10.1111/nep.12505
    [31] Parfey PS, Drüeke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis:the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial[J]. Clin J Am Soc Nephrol, 2015, 10:791-799. doi:  10.2215/CJN.07730814
    [32] Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet:the EVOLVE trial[J]. J Clin Endocrinol Metab, 2013, 98:4834-4844. doi:  10.1210/jc.2013-2975
    [33] Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2015, 87:846-856. doi:  10.1038/ki.2014.349
    [34] Raggi P, Chertow GM, Torres PU, et al. The advance study:a randomized study to evaluate the effects of cinacalcet plus low-dosevitamin D on vascular calcification in patients on hemodialysis[J].Nephrol Dial Transplant, 2011, 26:1327-1339. doi:  10.1093/ndt/gfq725
  • 加载中
计量
  • 文章访问数:  189
  • HTML全文浏览量:  5
  • PDF下载量:  951
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-11-08
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!